Amivantamab Shows Efficacy In Pts With Advanced NSCLC

August, 08, 2023 | NSCLC (Non-Small Cell Lung Cancer), Popular


  • The phase 1 CHRYSALIS study evaluated amivantamab (ami) for treating advanced non-small cell lung cancer with EGFR Ex20ins mutations.
  • Patients who had experienced disease progression on platinum-based chemotherapy were enrolled in the study.
  • The study demonstrated the effectiveness of amivantamab in treating advanced NSCLC with EGFR Ex20ins mutations across diverse patient groups and prior treatment backgrounds.

The CHRYSALIS study reported the long-term outcomes of utilizing amivantamab (ami) to treat advanced non-small cell lung cancer (NSCLC).

Patients with EGFR Ex20ins advanced NSCLC who had experienced disease progression on platinum-based chemotherapy were selected for recruitment in the CHRYSALIS study. Those who were administered the approved phase II dose of 1050 mg (1400 mg if their weight was ≥80 kg) by June 8, 2020, were eligible for inclusion. The investigator evaluated the response to the treatment.

The trial included 114 individuals, with a median follow-up duration of 19.2 mo and 48 (42%) pts alive. Investigators assessed the overall response rate (ORR) at 37% (95% CI, 28-46) with a median duration of response at 12.5 months (95% CI, 6.9-19.3), the median progression-free survival (PFS) was 6.9 months (95% CI, 5.6-8.8), and the median overall survival was 23 months (95% CI, 18.5-29.5). The activity was observed across all subgroups, including the elderly (with an ORR of 32% and 33% for age ≥65 and ≥75, respectively), heavily pretreated pts (with an ORR of 53% for >2 prior lines, 42% for prior immunotherapy, and 52% for prior EGFR TKI therapy), or those sensitive or resistant to prior platinum-based chemotherapy (with an ORR of 36% and 31%, respectively). No new safety concerns were found. Rash (89%) and infusion reactions (67%) were common side effects. 42% of pts (n=48) were administered ami for 12+ cycles (28-day). Additionally, 13% of pts (n=15) are still undergoing treatment, with 11 positive responses and four with stable diseases. Patients took ami for a median of 2.6 years. An analysis will be presented by comparing sustained clinical benefit vs. no benefit (≥12 cycles on ami), including plasma ctDNA data.

Ami showed efficacy in post-platinum pts suffering from EGFR Ex20ins NSCLC, regardless of age, prior treatments, platinum sensitivity, or refractory status. Moreover, a subgroup of pts experienced extended benefits, which will undergo further scrutiny and examination.


Clinical Trial:

Lopez, P.G., Girard, N., Cho, B.C., Sabari, J., Spira, A., Sanborn, R.E.E., Goto, K., Yang, J.C., Curtin, J., Lyu, X., He, A., Penton, J., Edwards, J., Massin, G.L., Xia, K., Chioda, M., Thayu, M., Knoblauch, R.E., Mahadevia, P., Leighl, N. Journal of Thoracic Oncology (2023).

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy